secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001104659-24-089936
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed
--------------------------------------------------------------------------------

- Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.
- Net loss $4.3M ($0.21 per share) vs $14.0M loss a year ago; operating loss $8.2M vs $11.4M.
- Closed up to $50M debt facility with OrbiMed; drew $25M at close; cash $16.5M at June 30.
- Warrant exchange completed; 79% of public warrants tendered, simplifying capital structure.
- Expects final Phase 1 data for nelitolimod in uveal melanoma and pancreatic cancer in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/0001104659-24-089936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924089936/tm2421775d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer